TECLens Secures $9.3 Million Series A Funding to Advance Its Non-Invasive Refractive Technology – TECLens
Summary
This collective backing of our investors is a powerful endorsement of both our quantitative corneal cross-linking technology and our mission to deliver a non-invasive and cost-effective refractive treatment for millions of people with vision disorders. Were honored by their support and view this as a strong validation of our innovative approach to addressing both refractive and therapeutic unmet needs in eye care.Traditional CXL uses riboflavin and ultraviolet light to strengthen the cornea. TECLens proprietary Quantitative Corneal Cross-Linking (qCXL) is designed to deliver a pre-calculated pattern and dose of UV light based on a computational biomechanics model of each patients eye. Our innovative CXLens\xae system uses patterned ultraviolet (UV) light to gently reshape the cornea with continuous biomechanical control. TECLens breakthrough technology aims to set a new standard in precision, accessibility, and patient experienceredefining vision correction with innovation that improves quality of life.To learn more visit www.teclens.com and follow us on LinkedIn.